Sac-TMT Plus Pembrolizumab Extends Median PFS to 15.0 Months in PD-L1-Negative Advanced NSCLC
Start here
In the phase III OptiTROP-Lung06 study, sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab met its primary endpoint in a head-to-head comparison for patients with PD-L1-negative (TPS <1%), driver-gene-negative advanced nonsquamous non-small cell lung cancer. The combination extended median progression-free survival from 5.7 months to 15.0 months, with a hazard ratio of 0.49 and P <0.0001. The results position the antibody-drug conjugate plus immunotherapy pairing as a candidate option in a population with limited established treatments. Outcomes beyond the primary endpoint, such as overall survival and safety data, are not yet part of the reported results.
Written by a model from the reports · updated 40 min ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickNMPA Accepts Merck's Pembrolizumab Plus Sac-TMT Filing for First-Line PD-L1-Negative Non-Squamous NSCLC
NMPA has accepted Merck's marketing application for subcutaneous pembrolizumab plus sac-TMT (sacituzumab tirumotecan) as first-line therapy for PD-L1-negative non-squamous NSCLC. The filing is based on positive results from the Phase 3 registrational OptiTROP-Lung06 study, which used pembrolizumab plus chemotherapy as a head-to-head control and was selected for an LBA at the ESMO congress.
- mp.weixin.qq.comPickOptiTROP-Lung06 Phase III: Sac-TMT Plus Pembrolizumab Extends Median PFS to 15.0 Months in PD-L1-Negative Driver-Negative Advanced Nonsquamous NSCLC
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab met the primary endpoint in the head-to-head phase III OptiTROP-Lung06 study, extending median PFS from 5.7 months to 15.0 months in patients with PD-L1-negative (TPS <1%), driver-gene-negative advanced nonsquamous NSCLC (HR 0.49; 95% CI 0.36–0.65; P <0.0001).
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 28 12:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.